SAN DIEGO, Dec. 21, 2020 — Janux Therapeutics today announced the company’s President and CEO, David Campbell, Ph.D., will provide a company presentation at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. The presentation will delve into the company’s proprietary Tumor Activated T Cell Engager (TRACTrTM) technology to engineer novel, T-cell engager drug candidates and will be available for on-demand viewing beginning Monday, January 11, 2021, at 6:00 AM Eastern Time on the HCW conference website.
T cell engagers are an emerging class of immunotherapies that bind to a tumor cell and recruit a patient’s T cells to eradicate tumor cells, but previous technologies have been constrained by dose-limiting toxicities, poor pharmacokinetic profiles, and attenuated efficacy. Janux’s proprietary TRACTr technology is designed to overcome these limitations by integrating tumor-specific activation with crossover pharmacokinetics to produce best-in-class T cell engager therapeutics. In preclinical studies, Janux TRACTr drug candidates have demonstrated comparable anti-tumor efficacy relative to standard T cell engagers but lack the associated liabilities related to cytokine release, healthy tissue toxicities, or systemic immune activation.
About Janux Therapeutics
Janux Therapeutics is developing safe, effective novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple negative breast, and ovarian cancers. Janux technology can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. Janux was founded in the Avalon Ventures accelerator, COI Pharmaceuticals, Inc., in San Diego.
Jessica Yingling, Ph.D.
Little Dog Communication Inc.
David Campbell, Ph.D.